Q2 2026 earnings spotlight for Recursion Pharmaceuticals

Recursion Pharmaceuticals (RXRX) released its Q2 2026 results on 5 August, giving investors fresh data on revenue trends and ongoing losses as the company continues to invest in its drug discovery platform.

The company reported second quarter sales of US$7.3 million and total revenue of US$7.67 million, compared with US$19.1 million and US$19.22 million in the same period last year. Net loss for the quarter was US$131.01 million with a basic loss per share from continuing operations of US$0.25.

For the first six months of 2026, Recursion Pharmaceuticals recorded sales of US$13.61 million and revenue of US$14.14 million, compared with US$33.92 million and US$33.97 million a year earlier. Net loss for the half year was US$248.51 million and basic loss per share from continuing operations was US$0.47, compared with US$0.91 a year ago.

Following the Q2 2026 earnings release on 5 August, Recursion Pharmaceuticals' 1 day share price return of 1.26% and 7 day share price return of 7.33% contrast with a year to date share price return that is down 23.33% and a 1 year total shareholder return that is down 39.93%. This points to some short term momentum after a much weaker multi year total shareholder return that is down 85.67% over five years.

If Recursion's earnings update has you rethinking exposure to this corner of healthcare, it can be useful to compare it with a wider group of specialist peers through 42 healthcare AI stocks

Recursion Pharmaceuticals is putting serious capital behind a high tech drug discovery vision, yet the share price is still well below past levels even after the latest bounce. Is the current valuation sufficient compensation for that level of risk?

Most Popular Narrative: 63.5% Overvalued

Recursion Pharmaceuticals last closed at $3.22, while the most followed narrative on Simply Wall St places its fair value closer to $1.97, implying a steep premium to that view.

Recursion Pharmaceuticals (RXRX) one day will be the Palantir of biotechnology! With the CMO transitioning out as well as the former CEO RXRX now has a chance to take off! Vikki Goodman and Najat Khan can now lead RXRX back to respectability and acceptance as a real leader in biotechnology! Once the announcements start coming in on REC-4881 going to Phase 3 and beyond this stock will skyrocket! RXRX finally has the right people in place to do their jobs correctly! Many institutions will soon be coming in with more good news to follow!!!

The fair value view behind this Recursion Pharmaceuticals narrative leans heavily on ambitious revenue expansion, improving profit margins and a future earnings multiple usually linked with high growth software style companies. Curious which specific assumptions are doing the heavy lifting in that calculation.

Result: Fair Value of $1.97 (OVERVALUED)

However, Recursion Pharmaceuticals still faces execution risk on its clinical pipeline, and it relies on external partners whose shifting priorities could weaken long term revenue potential.

Another view on Recursion Pharmaceuticals' valuation

The first narrative tagged Recursion Pharmaceuticals as overvalued at a fair value of $1.97. Our DCF model tells a very different story. On this view, RXRX at $3.22 trades 60.5% below an estimated future cash flow value of $8.16, which points to a wide gap in expectations.

For investors, the key question is which story seems more realistic given Recursion Pharmaceuticals' current losses and revenue forecasts, and how much uncertainty you are willing to accept in exchange for that potential upside.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Recursion Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

This mix of optimism and concern around Recursion Pharmaceuticals can feel conflicted, so it helps to check the numbers yourself and move quickly to your own judgement. To see how the current bull and bear arguments balance out in one place, start with these 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Recursion Pharmaceuticals?

If Recursion Pharmaceuticals has sharpened your focus on risk, reward and valuation, now is the moment to broaden your watchlist using targeted screeners that surface clear opportunities.

• Spot potential bargains early and review companies that currently screen as 49 high quality undervalued stocks so you do not overlook stocks that may already be priced for pessimism.
• Prioritise staying power and assess businesses featured in the solid balance sheet and fundamentals stocks screener (49 results) to focus on companies with financial positions that may handle tougher conditions.
• Hunt for fresh ideas and scan the screener containing 19 high quality undiscovered gems before others catch on to lesser known stocks with strong underlying fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.